Baseline characteristics

A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma. · Source last updated 2014-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      5

   units

   Participants

groups

1. description

   Participants received single doses of rituximab 750 mg/m\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.

   id

   BG000

   title

   Rituximab, Cytarabine, and MTX

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            47

            spread

            8.23

            upper Limit

            68

            value

            59.8

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            2

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            3

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

population Description

Safety population: all participants who received any amount of study drug.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice